
Wednesday, May 21, 2025 4:10:39 AM
"Recently, the Securities and Exchange Commission filed a complaint against Curt Kramer and three companies owned by Kramer, 1800 Diagonal Lending [color=red][/color]Company, LLC, Power Up Lending Group, Ltd., and Geneva Roth Remark Holdings, Inc. (Securities and Exchange Commission v. Power Up Lending Ltd., et al., No. 1:24-cv-03498). The SEC alleges that Kramer, by making convertible loans to microcap companies through 1800 Diagonal, Power Up and Geneva Roth, acted as a securities dealer without having the required securities licenses. To understand the case, and its ramifications, we first need to understand how these loans work"
https://kjk.com/2024/06/20/sec-brings-action-against-convertible-debt-lender/
Why Did the SEC Pursue Kramer?
Kramer and his companies aren’t the only ones offering convertible debt to small publicly traded companies. In the complaint, the SEC referred to Kramer as a “two-time recidivist violator of the federal securities laws,” but there appear to be some other reasons why the SEC is pursuing Kramer. In our experience, most of these convertible loans are only convertible if the borrower defaults, meaning that if the borrower repays the loan on time, then the lender does not have the right to convert the loan. For these loans, the conversion right is similar to a type of security that protects the lender — if the borrower is unable to pay, the lender converts and sells shares until the loan is considered repaid. However, most of Kramer’s loans were convertible after six months, regardless of whether the loan was in default, and some were converted in full before they were due (the six-month waiting period complies with SEC Rule 144, which allows a borrower to treat the shares as having been paid for when the loan was made, and freely sell them into the market after six months have elapsed without registration). In these cases, Kramer wasn’t protecting himself when a borrower couldn’t repay a loan. Instead, it appears he made the loans with the intent to convert at a discount and profit by selling the shares in the market. And profit he did. According to the complaint, from January 2018 to March 2023, Kramer’s companies made at least $60 million selling converted shares in the market after investing in approximately 325 issuers in nearly 2,000 transactions and converting loans into more than 90 billion newly-issued shares of common stock.

Recent TWOH News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2025 09:13:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2025 04:14:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/02/2025 08:43:22 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/14/2025 08:58:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2025 07:32:06 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2025 12:35:31 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/14/2025 06:44:17 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/14/2025 06:43:35 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/28/2025 11:12:00 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/24/2025 01:19:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2025 04:13:35 PM
- Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 01/10/2025 04:09:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/30/2024 09:12:49 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/18/2024 10:18:48 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2024 09:03:41 PM
Branded Legacy Inc. Announces Leadership Transition and Pending Merger with Innovative Addiction Therapeutics Company Projecting $40 Million in First-Year Revenue • BLEG • Jul 14, 2025 1:23 PM
VAYK Project 100% Revenue Growth Before Half Year Report • VAYK • Jul 14, 2025 8:58 AM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM